Algorae Pharmaceuticals Limited
Algorae Pharmaceuticals Limited
Your view on LVCLF
Overview
What the company does, where it operates, and who runs it.
About Algorae Pharmaceuticals Limited
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- David Richard Hainsworth
- Headquarters
- Tower 2, Melbourne, NSW, AU
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- David Richard Hainsworth
- Headquarters
- Tower 2, Melbourne, NSW, AU
Algorae Pharmaceuticals Limited, a pharmaceutical development company, engages in the research and development of living cells technologies primarily in New Zealand.
The company's product pipeline includes AI-116, a novel combination drug candidate, which includes cannabidiol and an off-patent pharmaceutical ingredient for the of treatment for dementia, including Alzheimer's disease; NTCELL, an alginate coated capsule to target the treatment of Parkinson's disease; and AI-168, a novel combination drug candidate made up of a cannabinoid and an off-patent pharmaceutical ingredient to treat cardiovascular disease, including hypertension.
It is also developing AlgaraeOS in partnership with the University of New South Wales, an artificial intelligence platform for biopharmaceutical prediction of both fixed dose combination drug targets and repurposed drug targets agnostic to medical indication.
The company was formerly known as Living Cell Technologies Limited and changed its name to Algorae Pharmaceuticals Limited in September 2023. Algorae Pharmaceuticals Limited was founded in 1987 and is based in Melbourne, Australia.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Algorae Pharmaceuticals Limited, and the rating behind it. LVCLF last traded at $0.0079; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Algorae Pharmaceuticals Limited. Starting points for Algorae Pharmaceuticals Limited: beta 0.18 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Algorae Pharmaceuticals Limited. Algorae Pharmaceuticals Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Algorae Pharmaceuticals Limited. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Algorae Pharmaceuticals Limited. Algorae Pharmaceuticals Limited has reported as a listed company since 2010. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Algorae Pharmaceuticals Limited valued side by side against its closest peers. Algorae Pharmaceuticals Limited is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Algorae Pharmaceuticals Limited, and how their positions are changing. At a $13.4M market value, institutional positions materially move Algorae Pharmaceuticals Limited's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Algorae Pharmaceuticals Limited executives and directors. Shares of Algorae Pharmaceuticals Limited have traded between $0.0015 and $0.0079 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Algorae Pharmaceuticals Limited. Algorae Pharmaceuticals Limited is a $13.4M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Algorae Pharmaceuticals Limited. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Algorae Pharmaceuticals Limited. Coverage tracks Algorae Pharmaceuticals Limited within Biotechnology (Healthcare). Press releases and market coverage, newest first.